

Nektar Therapeutics (NKTR) - Financial and Strategic SWOT Analysis Review

URL:	https://marketpublishers.com/r/N4C8EF32BC6EN.html
Date:	June 6, 2018
Pages:	51
Price:	US\$ 125.00
ID:	N4C8EF32BC6EN

Nektar Therapeutics (NKTR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company's operations and business divisions.
- Corporate strategy – Analyst's summarization of the company's business strategy.
- SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives' employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Nektar Therapeutics (Nektar) carries out discovery and development of novel therapeutic drug candidates based on its PEGylation and advanced polymer conjugate technology platforms to address unmet medical needs. The company's technology platforms offer a wide array of functional attributes, which optimizes and enhances the profile of wide range of molecules including many classes of drugs targeting numerous disease areas. The company's products focus on various therapeutic areas, including, cancer, pain, infections and immunology among others. Its research and development activities involve peptides, proteins, antibodies, small molecule drugs, and other potential biologic drug candidates. Nektar Therapeutics is headquartered in San Francisco, California, the US.

Nektar Therapeutics Key Recent Developments

May 10,2018: Nektar Therapeutics Reports Financial Results for the First Quarter of 2018

Mar 01,2018: Nektar Therapeutics Announces Fourth Quarter And Year-End 2017 Financial Results
Nov 22,2017: Nektar Announces Key Executive Promotions to Drive the Continued Growth of the Company's Immuno-Oncology Pipeline
Nov 07,2017: Nektar Therapeutics Reports Financial Results for the Third Quarter of 2017
Sep 21,2017: Nektar Therapeutics Appoints Biotechnology Executive Jeff Ajer as New Board Member

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table of Content

SECTION 1 - ABOUT THE COMPANY

Nektar Therapeutics - Key Facts
Nektar Therapeutics - Key Employees
Nektar Therapeutics - Key Employee Biographies
Nektar Therapeutics - Major Products and Services
Nektar Therapeutics - History
Nektar Therapeutics - Company Statement
Nektar Therapeutics - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Nektar Therapeutics - Business Description
Nektar Therapeutics - Corporate Strategy
Nektar Therapeutics - SWOT Analysis
SWOT Analysis - Overview
Nektar Therapeutics - Strengths
Nektar Therapeutics - Weaknesses
Nektar Therapeutics - Opportunities
Nektar Therapeutics - Threats
Nektar Therapeutics - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY'S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Nektar Therapeutics, Recent Deals Summary

SECTION 5 – COMPANY'S RECENT DEVELOPMENTS

May 10, 2018: Nektar Therapeutics Reports Financial Results for the First Quarter of 2018
Nov 22, 2017: Nektar Announces Key Executive Promotions to Drive the Continued Growth of the Company's Immuno-Oncology Pipeline
Nov 07, 2017: Nektar Therapeutics Reports Financial Results for the Third Quarter of 2017
Sep 21, 2017: Nektar Therapeutics Appoints Biotechnology Executive Jeff Ajer as New Board Member
Aug 08, 2017: Nektar Therapeutics Reports Financial Results for the Second Quarter of 2017
May 09, 2017: Nektar Therapeutics Reports Financial Results for the First Quarter of 2017
May 03, 2017: Nektar Therapeutics appoints new head of clinical development for immunology program
Mar 01, 2017: Nektar Therapeutics Reports Fourth Quarter and Year-End 2016 Financial Results

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

Nektar Therapeutics, Key Facts
Nektar Therapeutics, Key Employees
Nektar Therapeutics, Key Employee Biographies
Nektar Therapeutics, Major Products and Services
Nektar Therapeutics, History

Nektar Therapeutics, Other Locations
Nektar Therapeutics, Subsidiaries
Nektar Therapeutics, Key Competitors
Nektar Therapeutics, Ratios based on current share price
Nektar Therapeutics, Annual Ratios
Nektar Therapeutics, Annual Ratios (Cont.1)
Nektar Therapeutics, Interim Ratios
Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Nektar Therapeutics, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

LIST OF FIGURES

Nektar Therapeutics, Performance Chart (2013 - 2017)
Nektar Therapeutics, Ratio Charts
Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018

COMPANIES MENTIONED

Savient Pharmaceuticals Inc
Novo Nordisk AS
NOF Corporation
Mountain View Pharmaceuticals Inc
MacroGenics Inc
Juno Therapeutics Inc
Dr. Reddy's Laboratories Ltd
Celgene Corp
Biogen Inc

I would like to order:

Product name: Nektar Therapeutics (NKTR) - Financial and Strategic SWOT Analysis Review
Product link: <https://marketpublishers.com/r/N4C8EF32BC6EN.html>
Product ID: N4C8EF32BC6EN
Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service: office@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click 'BUY NOW' button on product page <https://marketpublishers.com/r/N4C8EF32BC6EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
E-mail:
Company:
Address:
City:
Zip/Post Code:
Country:
Tel:
Fax:
Your message:

* All fields are required

Customer Signature _____

Please, note that by ordering from MarketPublisher.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms_conditions.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to **+44 20 7900 3970**